← FDA DRUG APPROVALS

FDA NDA · NDA019350

CUPRIC SULFATE

Sponsor: ABRAXIS PHARM

APPLICATION
NDA019350
TYPE
NDA
ORIGINAL APPROVAL
1987-05-05
LATEST ACTION
1992-06-09
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CUPRIC SULFATE · ReferenceDiscontinued
CUPRIC SULFATE EQ 0.4MG COPPER/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION

Approval history

1992-06-09Labeling · Supplement 3 · standardAP
1990-05-15Labeling · Supplement 2 · standardAP
1987-05-05Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →